The 10-second takeaway
For the quarter ended March 24 (Q2), Hologic met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share shrank to a loss.
Margins contracted across the board.
Hologic reported revenue of $471.2 million. The 20 analysts polled by S&P Capital IQ foresaw revenue of $473.8 million on the same basis. GAAP reported sales were 7.4% higher than the prior-year quarter's $438.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.33. The 24 earnings estimates compiled by S&P Capital IQ predicted $0.33 per share. GAAP EPS were -$0.15 for Q2 against $0.31 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 57.4%, 310 basis points worse than the prior-year quarter. Operating margin was 12.5%, 260 basis points worse than the prior-year quarter. Net margin was -8.5%, 2,730 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $482.3 million. On the bottom line, the average EPS estimate is $0.35.
Next year's average estimate for revenue is $1.92 billion. The average EPS estimate is $1.38.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 692 members out of 712 rating the stock outperform, and 20 members rating it underperform. Among 196 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 191 give Hologic a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hologic is outperform, with an average price target of $23.05.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Hologic the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Hologic to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's Why Cynosure, Inc. is Soaring Today
Shares skyrocket after the company accepts a buyout offer from Hologic.
Why Hologic's Shares Are Stumbling Today
Tepid guidance for growth this year is weighing down shares.
Why Hologic Inc. Shares Soared Today
Hologic sales and profit eclipsed Wall Street expectations.